Seeking Alpha
 

Micromet, Inc. (MITI)

- NASDAQ
MITI is defunct.
  • Jan. 26, 2012, 8:35 AM
    Micromet (MITI) surges 34% to $11.07, which is just above Amgen's (AMGN) $11/share offer for the company.
    | 1 Comment
  • Jan. 26, 2012, 8:20 AM
    More on Amgen (AMGN) / Micromet (MITI) deal: The acquisition provides Amgen with blinatumomab, a leukemia treatment in Phase 2 trials. The offer of $11/share is a 33% premium to Micromet's close yesterday. (PR)
    | Comment!
  • Jan. 26, 2012, 8:08 AM
    Amgen (AMGN) agrees to acquire Micromet (MITI) for $11/share, or $1.16B. (PR)
    | Comment!
  • Jul. 11, 2011, 9:13 AM
    Micromet (MITI) says it entered into a collaboration agreement with Amgen (AMGN) for the research of BiTE antibodies designed to direct the body's cell-destroying T-cells against tumor cells, representing a new therapeutic approach to cancer therapy. MITI +4.5%, AMGN -0.8% premarket. (PR)
    | Comment!
  • Jul. 11, 2011, 9:05 AM
    Premarket gainers: ARJ +11%. AIS +8%. PSTI +6%. MITI +4%. SIRI +3%.
    Losers: ING -7%. NBG -6%. BBVA -6%. STD -5%. IRE -5%. TEF -5%. TEF -5%. RENN -5%. E -5%. BCS -4%. DB -4%. LYG -4%. TS -4%. ALU -4%. CTIC -4%. NOK -4%. BUD -4%. TOT -4%. TSEM -4%. SI -3%. FRO -3%. CPST -3%. MT -3%. SDRL -3%. RCL -3%. CS -3%. STO -3%. AMD -3%. UN -3%. SINA -3%.
    | Comment!
  • Jun. 10, 2011, 8:54 AM
    Micromet (MITI +11.5%) says 75% of patients in a small phase-2 trial of its leukemia treatment blinatumomab achieved a complete remission, with no remaining cells in blood or bone marrow. MITI says the results are particularly striking given that the majority of enrolled patients had characteristics typically associated with a dismal outlook. (PR)
    | Comment!
  • Nov. 11, 2010, 9:00 AM
    Premarket gainers: LVLT +9%. GERN +8%. DNDN +6%. IR +4%.
    Losers: ANW -43%. CSCO -17%. MITI -11%. SOLF -10%. RINO -9%. IRE -9%. AIB -8%. TSEM -8%. EXK -8%. CLNE -7%. LLNW -7%. JNPR -6%. ALU -6%. ALTR -5%. GKK -5%. BRCM -4%. CTIC -4%. WPI -4%. TTM -4%. GLP -4%. PCBC -4%. AMSC -4%. STD -4%. ASML -4%.
    | Comment!
  • Oct. 29, 2009, 9:00 AM
    Premarket gainers: AMSC +15%. AIXG +12%. RBS +12%. PQ +11%. LYG +10%. AKAM +10%. MITI +10%. ING +9%. FNM +8%. ABK +8%. CTIC +8%. DB +8%. FITB +7%. FRE +7%. SWSI +7%. BCS +6%. MOT +6%. IRE +6%. ALU +6%. TCK +5%. RCL +5%. RTP +5%. CS +5%. HL +5%. ACGY +5%. MT +5%. GNW +5%. HGSI +5%. FAS +5%. GOLD +5%. LVS +5%. HIG +5%. MGM +4%. CNO +4%. ASML +4%. NCS +4%. LCC +4%. VALE +4%. PG +4%.
    Losers: FSLR -15%. BCRX +4%. FLS -4%.
    | Comment!
  • Jun. 8, 2009, 9:21 AM
    Premarket gainers: PKT +102%. ANPI +56%. MITI +30%. DYAX +18%. SLM +14%. SVA +13%. ARNA +12%. XOMA +9%.
    Losers: AIB -13%. LYG -11%. SAY -7%. MT -6%.
    | Comment!
Visit Seeking Alpha's
Company Description
Currently, there's no company description for MITI.
Sector: Healthcare
Industry: Biotechnology
Country: United States